Remote interactions between two d-dimensional distributed quantum systems： nonlocal generalized quantum control-NOT gate and entanglement swapping

We present a systematic simple method to implement a generalized quantum control-NOT （CNOT） gate on two d-dimensional distributed systems. First, we show how the nonlocal generalized quantum CNOT gate can be implemented with unity fidelity and unity probability by using a maximally entangled pair of qudits as a quantum channel. We also put forward a scheme for probabilistically implementing the nonlocal operation with unity fidelity by employing a partially entangled qudit pair as a quantum channel. Analysis of the scheme indicates that the use of partially entangled quantum channel for implementing the nonlocal generalized quantum CNOT gate leads to the problem of ＇the general optimal information extraction＇. We also point out that the nonlocal generalized quantum CNOT gate can be used in the entanglement swapping between particles belonging to distant users in a communication network and distributed quantum computer.[第一段]     

利用超分次技术进行肿瘤治疗的探讨

以人类肝癌细胞SMMC-7721和正常肝细胞L02为研究对象，以这两种细胞0．3Gy时超敏感性的存活数据为基础，从理论上探讨了γ射线照射时，用超分次技术治疗肝癌的可能性。经过计算发现:如果目标肿瘤和周围的正常组织超敏感性的存活差异提高到3％，即可利用超分次技术对肿瘤进行治疗。应用超分次进行分次照射时，照射的结果与分次的间隔时间有关。对这一现象的机理进行了一定的探讨，发现时间间隔与细胞G2期的长短可能存在一定的相关性。Based on the survival data of human hepatoma SMMC-7721 and normal liver L02 cells irradiated with γ-rays at 0.3 Gy and 2 Gy, the possibility of uhra-fractionated radiotherapy is discussed in this paper. According to calculations, it is found that if the difference in cell survival between target tumor and adjacent normal tissue is up to 3%, radiotherapy using HRS would be realized through uhra-fractionation. Furthermore, the low-dose response is time-dependent. After analyzing this phenomenon, it was pointed that there would be a correlation between fractionation interval and the duration of cell G2 phase.     

重离子束治疗肿瘤临床研究

文章综述了重离子束在物理学、生物学、临床治疗等方面的优势,以及在放射生物学方面的基础实验研究内容。分析总结了国内外重离子束辐照治疗肿瘤的临床研究结果。其中,日本已接受治疗了约6 000 名不同类型的肿瘤患者,并取得较高的局部控制率和生存率;德国在头颈部肿瘤临床治疗方面取得了巨大的成功;在兰州重离子研究装置(HIRFL) 肿瘤治疗终端上,中国科学院近代物理研究所联合甘肃省肿瘤医院及兰州军区总医院对肿瘤患者的重离子治疗已进入临床试验阶段。甘肃省肿瘤医院治疗结果显示:43 例患者通过影像学检查评价疗效,客观有效率(CR+PR)为71.4%,主要急性放射损伤为1-2 级皮肤反应(红斑形成和脱皮),发生率为61.9%,治疗1 个月后随访结果显示重离子束(12C6+)对深部肿瘤具有较好的局部控制作用,且无严重不良反应发生。This article reviews the advantages of heavy ion in physical, biological and clinical aspects, discusses the radio-biological basis of experiment research, and summarizes clinical results of heavy ion beam treatment on tumor at home and abroad. Japan has accepted and treated about 6000 cancer patients of different types with high local control rates and survival ones. Germany has achieved great success in head and neck tumor clinical treatment. Institute of Modern Physics, Chinese Academy of Sciences (IMP-CAS), Tumor Hospital of Gansu Province and Lanzhou General Hospital of PLA have begun clinical trial on heavy ion treatment of deep-seated tumors after the shallow-seated tumor therapy has been done at HIRFL (Heavy Ion Research Facility in Lanzhou). The treatment results of Tumor Hospital of Gansu Province show that the objective response rate (CR+PR) is 71.4% and the rate of 1-2 levels radiation injury to skin reactions (erythema and desquamation) is 61.9% when we evaluate the 43 patients by means of maging. The results of case follow-up after treatment in 1 month indicate that the deep-seated tumor therapy with heavy ion beam has high local control rates without severe adverse effect.